The Intercept @theintercept
Gilead could profit from remdesivir even if it was priced at just $1 a day. Instead the drug, which was rolled out with the help of the Trump administration, will cost insurers between $3,120 for a five-day course and $5,720 for a 10-day course. https://t.co/m9ZQ8L153y — PolitiTweet.org